| INTRODUC TI ON
Endometrial cancer (EC) is the sixth most common cancer among women worldwide and the most common gynecological cancer in the western world. 1 In Norway, EC incidence rates have increased markedly in the last decades, 2 with age-standardized rates of 19.7 per 100 000 person-years reported in the period 1982-1986 and 27.6
per 100 000 person-years in the period 2012-2016. 3 Furthermore, EC incidence rates in Norway are predicted to increase by 57% in 2025, compared with the rates observed in 2005. 4 Among women, menstrual and reproductive factors, such as earlier age at menarche, [5] [6] [7] [8] [9] later age at menopause, [5] [6] [7] [8] 10, 11 nulliparity, and/or nulligravidity, [5] [6] [7] [8] [9] [12] [13] [14] [15] [16] [17] contribute to hormonal changes, the effects of which play an important role in the development of hormone-related cancers. Indeed, these factors might be linked to prolonged, excessive exposure of endometrial cells to estrogen, leading to an increased EC risk. Conversely, full-term pregnancies, 9, 14 later age at last birth, 5, 16, 17 and breastfeeding 5, 9, 12, 13 play a protective role in EC risk due to prolonged exposure to progesterone. Studies that investigated the relation between incomplete pregnancies and EC risk provided controversial results,
showing no association, 5, 12, [18] [19] [20] [21] inverse association 9, 16, 22 or even increased risk. 8 Lifetime number of years of menstruation (LNYM)
can be used as a composite variable to summarize the effect of the above-mentioned factors and indirectly measure cumulative exposure to endogenous hormones during a woman's reproductive years.
Several epidemiological studies have prospectively investigated the combined impact of menstrual and reproductive factors on EC risk. The most cited reports investigated the effect of number of years of ovulation or total menstrual lifespan. 5, 8, 9 However, studies based on postmenopausal populations from the USA (IOWA population) 8 and China 9 were limited by a small number of cancer cases, and they presented age-adjusted analyses only, failing to control for potential risk factors. The study by Dossus et al. 5 included both premenopausal and postmenopausal women with heterogeneous information on breastfeeding and number of full-term pregnancies from different European countries. That study presented risk estimates per year of menstruation, but did not show any association between increasing LNYM and EC.
When strong associations are observed between an outcome and a risk factor, population attributable fraction (PAF) is often used to measure the impact of that risk factor on a population level. 23 Although recent studies have investigated the PAF of EC in relation to physical activity (PA), obesity, menopausal hormone therapy (MHT) use, parity, and breastfeeding, 14, 24, 25 
| Study sample
Women who reported that their periods stopped spontaneously for inclusion (n = 159 246). We then excluded participants with prevalent cancer (n = 7246), those who reported hysterectomy or oophorectomy at baseline or follow up (n = 12 221), and those who emigrated or died before the start of follow up (n = 7). We further excluded women with missing information on years of menstruation (n = 11 113), which included missing information on age at menarche (n = 2274) and ever-use of oral contraceptive and duration (n = 8839). Women with missing information on the selected confounders: height or weight (n = 2666), 24 smoking status (n = 557), and PA (n = 7847) were also excluded.
Hence, the final study cohort included 117 589 postmenopausal women. Menopausal hormone therapy is an established risk factor for EC 35 and is also associated with menstrual characteristics.
| Assessment of covariates and calculation of lifetime number of years of menstruation
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However, we decided not to include MHT in the multivariable models, as this variable is included in the calculation of LNYM through age at menopause.
| Identification of endometrial cancer
Women with EC were identified through linkage to the Cancer Registry of Norway via the unique identification number assigned to each resident of Norway. The registry provides detailed information on all cancer sites and histology, and covers the whole population of Norway. 
| Statistical analyses
As we studied postmenopausal women, age at inclusion into the present study was set as the age at menopause. Therefore, we calculated person-years from age at menopause to the date of any incident cancer diagnosis (except basal cell carcinoma), emigration, death, or the end of the study (31 December 2014), whichever came first.
We used Cox proportional hazards regression, 39 33 450 with information on both these variables. Therefore, we constructed models with 2 new LNYM values, which were calculated in the same manner as LNYM above, but also subtracted 12 weeks for each incomplete pregnancy. The value LNYM_1 included both the abortion and exu-variables (n = 33 450), and LNYM_2 included just the abortion variable (n = 65 548). Using Cox regression, we then estimated the association between LNYM_1 and EC risk, and between LNYM_2 and EC risk (data not shown). A final sensitivity analysis was restricted to women who had never used oral contraceptives.
We calculated the PAF to estimate the proportion of EC that could have been prevented in the population if women had a lower LNYM, using the formula: PAF = Pe*(RRe-1)/[Pe*RR + (1-Pe)], where Pe is the proportion of LNYM in the study population, and RRe is the relative risk (RR) in the final baseline multivariable proportional hazards regression model, including all aforementioned confounders and BMI. We calculated two-sided 95% CIs for the PAFs using the PUNAF Stata module. 42 We constructed cumulative incidence rate plots for EC in the NOWAC Study and compared them with those of the cumulative incidence rate in the general Norwegian female population (see Supplementary material, Figure S2 ).
All the analyses were performed in 214 STATA version 14.0 (Stata Corp., College Station, TX, USA).
| Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The study was approved by the Regional Committee for Medical
Research Ethics and the Norwegian Data Inspectorate. All the participants were informed about the study objectives and provided informed consent. Our participants breastfed for on average around 7 months (SD 1.0), had a mean BMI of 24.3 (SD 3.9) kg/m 2 , and almost half had at least two children and were ever users of oral contraceptives (n = 47 287) ( Table 2) .
| RE SULTS
Although the test for interaction between BMI and LNYM was not statistically significant (P = .78), we decided to look at the association between EC risk and BMI in two categories, ≤24.9 and ≥25 (Table 3 ). When we did this, both age-adjusted and multivariable analysis showed a significant (P = .0001) increased EC risk with increasing LNYM. between PA (PA <5, PA ≥5) and BMI (BMI ≤24.9 and BMI ≥25) were not significant (Table 3) .
Calculations of PAF showed that if women with LNYM ≥35 could decrease their LNYM <35 years, 48% of EC could be avoided. The proportion of avoided cases increased to 64% and 67%, if LNYM was decreased to 20 and 25 years, respectively (see Supplementary material, Table S1 ).
| D ISCUSS I ON
To the best of our knowledge, this is the first large, nationally representative cohort study that estimated the fraction of EC in postmen- of several hormone-related factors. [43] [44] [45] [46] [47] [48] [49] In 1986, Pettersson et al.
were the first to present a clear, dose-response association and a 4-fold increased EC risk with a longer menstruation span. 50 Thereafter, other studies looked at this association using a prospective design. 5, 8, 9 All analogue cohort and case-control studies have substantial methodological heterogeneity in their construction of LNYM and in the number of potential confounders available for adjustment. 46 In addition, and in contrast to other studies, we used the highest LNYM category (LNYM ≥40 years) as the reference category, because there were fewer EC in the lowest category of LNYM, and our intention was to show the distribution of risk estimates in 5-year intervals.
When we ran analyses using our lowest LNYM category (LNYM <25) as a reference, women with >40 LNYM showed a 5-fold increased EC risk (HR = 5.0, 95% CI 3.10-8.03). Nevertheless, this methodological difference did not alter the significant dose-response association found in our study, which is in line with other earlier reports.
Despite the limited number of reports that directly investigated the association between EC risk and LNYM, there are numerous studies that indirectly confirmed this association by showing the effect of each individual component of LNYM. A woman's natural menstrual lifespan starts at menarche, is interrupted by pregnancies and breastfeeding periods, and ends with menopause. 50 All of these factors contribute to changes in lifetime exposure to natural estrogen and progesterone and may, therefore, contribute to endometrial carcinogenesis. However, the possible long-term consequences of each reproductive factor differ substantially and vary across individuals. 51 To minimize the possible influence of lifestyle risk factors on the association between LNYM and EC risk, we took into account the effect of BMI, MHT use, and diabetes. Obesity and overweight are reported to contribute to about 40% of EC cases, and according to several reports, they confer a 4-to 6-fold increase in risk. 52 However, when we adjusted for or stratified by BMI, the results and dose-response trend were lightly attenuated but remained significant, suggesting that LNYM and BMI have an independent effect on EC risk. These findings are in line with another recently published study, showing that, in comparison to genetic determinants, reproductive factors are less dependent on obesity and overweight with regard to EC risk. 45 We did not observe any changes in the main association when we stratified by diabetes and MHT. The possible effect of MHT use in our study was also ruled out by including this variable in multivariable-adjustment analysis and in the calculation of LNYM. The relation between LNYM and EC risk is clearly biologically plausible. In terms of EC development, there are 2 possible key mechanisms. The first one relates to the widely proposed "estrogen window hypothesis," which is based on incessant ovulation causing prolonged exposure to unopposed estrogen. 53 The second mechanism supports the theory that the increased number of periods and, therefore, cycles, creates incessant repeated disruption of the uterine lining and increases the probability of genetic alterations. 8 Previous studies reported a low incidence of breast and other estrogen-dependent malignancies among indigenous women. It has been shown that these women historically had fewer periods and ovulatory cycles during their life, due to multiple pregnancies and long periods of breastfeeding. 54 The main strength of our study is the population-based prospective design, as the NOWAC Study is representative of Norwegian middle-aged women. A good illustration of this is the cumulative incidence rate plots for EC constructed for both NORDCAN (Norway) 2 and NOWAC, which are matched by age group (see Supplementary material, Figure S2 ). Another important strength of our study is the large sample size, which gave sufficient statistical power to investigate the association between LNYM and EC risk, as well as the effect of important confounding factors. Being population-based, our study is of particular interest in showing the independent association between reproductive factors and EC risk, which can likely be extrapolated to similar populations. We observed normal or slightly increased BMI and few cases of diabetes among our participants, allowing us to propose that other factors might also contribute to the continuous increase in EC in Norway. Along with other Scandinavian countries, and in contrast to several other countries in Europe, Norwegian women had earlier access to oral contraceptives, which were widely used in this study population. 55 This allowed us to perform additional analyses among ever users and never users of oral contraceptives and conclude that the dose-response relation we observed between LNYM and EC risk is independent of oral contraceptive use. Moreover, 99%
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of the EC cases in our study were type 1, which is believed to be more strongly associated with reproductive factors, 38 so strengthening the plausibility of our findings. The results of sensitivity analyses also confirmed the validity of our LNYM variable, showing unchanged HRs regardless of which risk factors were included.
Our study also had several methodological limitations. First, we used information about past events in women's lives, hence misclassification of exposures may have occurred. However, given the prospective nature of our design, if recall errors exist, we would expect them to be nondifferential. Second, although we were able to include information on incomplete pregnancies for some women, a substantial proportion of women had missing data on these variables.
However, several studies with higher statistical power showed no biological evidence that incomplete pregnancies produce the equivalent long-term decrease in estrogen levels that full-term pregnancies do with regard to hormone-dependent cancers. 56 Third, due to lack of information on menstrual regularity, bleeding volume, anovulation, and cycle length, we cannot rule out the possibility of residual confounding. 57 Moreover, ovulatory cycles and LNYM might be independent risk factors, 58 and we could not address the potential effect of other bleeding problems, like secondary amenorrhea, that some women might experience during their reproductive life. Finally, due to a limited number of premenopausal EC in NOWAC, our analysis was restricted to postmenopausal women, which, on the other hand, allowed us to look at the effect of the entire menstrual span.
| CON CLUS ION
The results indicate that a higher LNYM increases EC risk among postmenopausal women. Our results support the hypothesis that LNYM is an important tool that represents the cumulative effect of several risk factors and can be used to predict EC risk at a population level, which is, in our opinion, a better indicator of risk than each individual component.
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